dstock07734
2 hours ago
Senior Scientist / Associate Director, Omics at insitro
The Opportunity
High quality data generation with state-of-the-art technologies that measure multiple cellular aspects is at the heart of Insitro's efforts to accelerate drug development. In particular the omics platform integrates state-of-the-art functional and observational genomics technologies to interrogate the genes, proteins, and signaling networks that characterize individual cellular states.
We are seeking a highly motivated and independent team member with deep expertise in sequencing based readouts. The successful candidate will possess a deep-knowledge of methods for NGS library preparation (RNA-seq, Ribo-seq, ATAC-seq, ChIP-seq, Hi-C, etc.) as well as hands-on experience with various sequencers (Illumina, Nanopore, PacBio, etc). You will work in a fast-paced and highly collaborative environment to address important questions from our research community. Specifically, you will employ the latest genomic tools to interrogate these questions in close collaboration with all teams across insitro. Your expertise will help the team navigate the complexities of generating high quality transcriptomics data and ensure that the protocols being developed are effective, performed to the highest rigor and in line with best practices in the field.
In this role, you will directly impact all target discovery and prioritization efforts, advance our understanding of diseases and aid the development of new treatments. In general, as a staff genomics scientist at insitro, you will be in charge of establishing platforms and workflows to enable the generation of high quality sequencing data, generating large scale datasets paired with other modalities, and enabling multimodal measurements and data integration. You will be part of a cross-functional team of life scientists, data scientists, bioengineers, software engineers, and machine learning scientists that strive to identify therapeutic targets and develop drugs of high efficacy and low toxicity.
You will be joining a vibrant biotech startup that has long-term stability, due to significant funding, and is in a high growth phase, and you will have many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro's culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Responsibilities
Implementing sequencing protocols and platforms (Illumina, PacBio, Nanopore, etc), as well as functioning independently to explore and develop new genomic technologies.
Leading and participating in collaborative genomic projects.
Responsible for interfacing with other labs and cores to identify opportunities for research & collaboration
Responsible for inventing, optimizing and maintaining state-of-the-art approaches in collaboration with scientists.
Responsible for working with scientists to develop project-specific experimental strategies, techniques, and procedures, and to interpret and model data.
Overseeing a range of duties supporting and developing laboratory operations and administration for sequencing workflows.
Writing protocols and presenting research work internally and externally.
About You
8+ years of working experience post MSc with sequencing based workflows and readouts. Must have hands-on experience with library quantification with ddPCR/qPCR and with operating various sequencers (Illumina, Nanopore, or PacBio). Must have hands-on experience with NGS library preparation, in particular with single cell sequencing library preparation (10X genomics, SMART-seq2 and Split-and-Pool methods, etc.)
Ability to work independently and lead projects.
Hands-on experience with spatial transcriptomics and/or proteomics data generation.
Some understanding of human physiology or disease biology (e.g. neurosciences, cancer biology).
Experience with CRISPR-based experiments (i.e. perturb-seq).
Ability to communicate effectively and collaborate with people of diverse backgrounds and job functions.
Passionate about troubleshooting, asking questions and learning independently.
Familiarity with software tools (e.g., bcl2fastq, cellranger) and bioinformatics.
Passion for making a difference in the world.
Nice to Have
Working knowledge of large-scale single cell / bulk CRISPR screens in various settings including in vivo, ex vivo, and cell line systems is highly desirable.
Experience with lab automation is highly desired.
Publication record of meaningful contributions to high-quality work in relevant computational biology, systems biology, life sciences, or biomedical venues.
First-hand experience studying diseases using omics data.Experience building genomics teams
https://boards.greenhouse.io/insitro/jobs/4379887006
biosectinvestor
3 hours ago
Sorry if I sounded grumpy. Understood. She did not sell them anything period and I do not believe they can monetize, directly, anything from doing NWBO’s manufacturing, especially not manually. I think the key point is, let’s not suggest anything was sold, to them, from NWBO, because there is nothing suggesting that. Let’s not feed shorts and then argue with them about things that are not real. Cognate can help other companies develop their own IP, but working with the cells was likely already part of the general art, and for the things NWBO patented, they’d need a license to use even if they have personnel who helped invent some ideas. And some ideas are likely less consequential than others. And of course Flaskworks creates a whole new class of technologies and patents.
skitahoe
3 hours ago
Unless I'm mistaken, substantial financial penalties could be involved, but unless the Govt. takes on the MM's, this is a civil suit and can't result in jail time. I doubt this will ever go to court where the govt. would see what's presented and could take action. I really believe that the SEC rarely digs into such cases, especially when it comes to OTC stocks, but anything is possible. The SEC has all to often ignored violation of their rules, in 2008 they went so far as to say for a certain period of time naked shorting of bank stocks would be prosecuted. In other words, for some brief period of time they would actually enforce the law. What is the good of having a law that's essentially being ignored and where you announce things are bad enough that you intend to prosecute it, but only for a short period of time.
Some people believe that over a billion shares of naked shorting has occurred here. To put it another way, that would be perhaps a half billion dollars worth of stock being issued that NWBO wasn't paid for if the average short was at $.50. What would NWBO's financial position look like if they had $.5 billion more in cash from sales of stock.
Gary
skitahoe
4 hours ago
Newman, we're in complete agreement if the UK approval comes in sometime in the next month or so and is a surprise. On the other hand, I would suspect that the smarter shorts are trying to slowly unwind their positions without driving the share price up. These people are well served by MM's trying to keep the share price low.
Let's hope it isn't much longer before it becomes clear that Posner's case will go to trial unless the MM's settle prior to that happening. I don't believe the MM's will risk going to trial which would expose them to SEC scrutiny, as well as a substantial risk of a verdict against them that could go into billions, or certainly hundreds of millions. The question may be, does Posner make them an offer to settle quickly, at a lower price, but convince them the longer they take, the higher the price will be. I would certainly hope that her lowest price is in the hundreds of millions.
I believe that no matter when the approval comes we'll have a short squeeze, there are certain people who'll simply have a short position that's so big they can't possibly eliminate it, but they may be trying to reduce it. I know some here who believe that if it takes another 2 months or more before we get the approval the lower $.30's aren't off the table. I don't think that possibility can be denied unless the company has other news that should buoy the stock between now and then. If I were short, I'd be working my way out today, but those who believe we could see low $.30's will probably hold their position in the belief that will happen.
Gary
skitahoe
4 hours ago
Please correct me if I'm wrong. As I remember it, NWBO announced that it was making certain material changes in the EDEN to make cleaning and maintenance of it better. I suspect that this was the result of an inspection of the EDEN by regulators who recommended the changes. I don't know this to be the case, but if it were wouldn't it be equally possible to believe the regulators were actually observing the operation of the units and perhaps studying the vaccine being manufactured in them.
I'm not saying this is the case, just looking at possibility. I don't believe the material changes would effect the output of the unit, especially if they're not in the disposable cassette, the only part that ever touches the vaccine. I believe they've ordered production models with the material changes required and hopefully will shortly have some operational at Sawston.
It's clear that LP is playing her cards close to the vest, she was more open about many things anticipated in the next 18 months, but short on specific goals or scheduling, something that is typical of biotech CEO's across the board. This was certainly the best presentation I've seen from her in the few years I've been an investor. I believe that she was being cautious about saying they still expect RFI's rather than saying we're currently at a period that's more than double where this is normally received, so it's very possible there will be no RFI's at all. In the back of my mind I believe that she'd be thrilled with an approval that totally shocked the shorts still working hard to manipulate the stock.
Gary